Table 3.

Liver Function in 31 Evaluable Patients According to HGV Status and Treatment Modalities After Completion of Drug Therapy

HGV-RNA
Positive Negative
BMT (n = 6) Chemotherapy (n = 4) BMT (n = 10)Chemotherapy (n = 11)
Maximum ALT, IU/L (mean ± SD) 88.0 ± 19.63-150,3-151 16.3 ± 0.4  37.2 ± 4.23-152 18.4 ± 5.0  
 Abnormal/total  6/6 0/4  4/10  0/11  
 % Patients with abnormal levels  100  0  40  0  
Mean ALT (mean ± SD) 44.9 ± 15.6  10.7 ± 0.8  20.9 ± 2.33-153 11.1 ± 2.9 
HGV-RNA
Positive Negative
BMT (n = 6) Chemotherapy (n = 4) BMT (n = 10)Chemotherapy (n = 11)
Maximum ALT, IU/L (mean ± SD) 88.0 ± 19.63-150,3-151 16.3 ± 0.4  37.2 ± 4.23-152 18.4 ± 5.0  
 Abnormal/total  6/6 0/4  4/10  0/11  
 % Patients with abnormal levels  100  0  40  0  
Mean ALT (mean ± SD) 44.9 ± 15.6  10.7 ± 0.8  20.9 ± 2.33-153 11.1 ± 2.9 

All of the patients in the table were negative for other hepatopathic factors, including HCV-RNA, HBs antigen, autoimmune antibodies, and drug use. The values of mean ALT represent the average of the mean ALT values of each patient measured during each month of the hospital course.

Abbreviation: ALT, alanine aminotransferase, normal value <40 IU/L.

F3-150

P = .0064 HGV-infected versus uninfected.

F3-151

P = .0189 BMT versus chemotherapy.

F3-152

P = .0003 BMT versus chemotherapy.

F3-153

P = .0005 BMT versus chemotherapy.

Close Modal

or Create an Account

Close Modal
Close Modal